01:52 AM EDT, 10/26/2026 (MT Newswires) -- Biosergen's (BIOSGN.ST) merger with Flerie was completed, with its operations and assets transferred to the life science investor's new subsidiary Flerie Invest. The biotechnology company said Oct. 23 that Flerie issued 2,667,234 new ordinary shares as merger consideration, bringing its total share count to 89,364,936. Biosergen shareholders will receive one Flerie share for every 31 Biosergen shares held as of Oct. 26, with distribution expected around Oct. 28.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.